news.bms.com

BMS Newsroom |

8/13/15 8:00 am EDT. FDA Approves U.S. Product Labeling Update for Sprycel (dasatinib) to Include Five-Year First-Line and Seven-Year Second-Line Efficacy and Safety Data in Chronic Myeloid Leukemia in Chronic Phase. 8/12/15 4:15 pm EDT. US Food and Drug Administration Extends Action Date for Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Untreated Advanced Melanoma. 8/4/15 8:00 am EDT. 8/3/15 9:00 am EDT. 7/29/15 7:00 pm EDT. 7/27/15 7:00 am EDT. 7/24/15 2:06 pm EDT.

http://news.bms.com/

OVERVIEW OF news.bms.com

TRAFFIC RANK

>1,000,000

REVIEWS

0

PAGES IN THIS WEBSITE

9

LINKS TO THIS WEBSITE

CONTACTS

ADDRESSES

SOCIAL LINKS

ONLINE SINCE

WEBSITE DETAILS

SEO

PAGES

SIMILAR SITES

TRAFFIC RANK FOR NEWS.BMS.COM

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

February

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Monday

TRAFFIC BY CITY

Sign up

CUSTOMER REVIEWS

Average Rating: 4.3 out of 5 with 4 reviews

5 star

1

4 star

3

3 star

0

2 star

0

1 star

0

Hey there! Start your review of news.bms.com

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

LOAD TIME

1.6 seconds

FAVICON PREVIEW

16x16

CONTACTS AT NEWS.BMS.COM

ADD CONTACT

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

CONTENT

PAGES IN
THIS WEBSITE

9

SSL

EXTERNAL LINKS

81

SITE IP

204.8.173.158

LOAD TIME

1.634 sec

SCORE

6.2

PAGE TITLE

BMS Newsroom | | news.bms.com Reviews

<META> DESCRIPTION

8/13/15 8:00 am EDT. FDA Approves U.S. Product Labeling Update for Sprycel (dasatinib) to Include Five-Year First-Line and Seven-Year Second-Line Efficacy and Safety Data in Chronic Myeloid Leukemia in Chronic Phase. 8/12/15 4:15 pm EDT. US Food and Drug Administration Extends Action Date for Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Untreated Advanced Melanoma. 8/4/15 8:00 am EDT. 8/3/15 9:00 am EDT. 7/29/15 7:00 pm EDT. 7/27/15 7:00 am EDT. 7/24/15 2:06 pm EDT.

<META> KEYWORDS

1 news

2 newsroom

3 press

4 press releases

5 media

6 BMS

7 BMY

8 NYSE:BMY

9 investigational compound

10 HIV

CONTENT

Page content here

KEYWORDS ON PAGE

next,last,search press releases,keywords,filter category,financial news,philanthropy news,r&d news,partnering news,investigational compound news,hepatitis c,oncology,filter year,reset

SERVER

Apache

CONTENT-TYPE

utf-8

GOOGLE PREVIEW

BMS Newsroom | | news.bms.com Reviews

https://news.bms.com

8/13/15 8:00 am EDT. FDA Approves U.S. Product Labeling Update for Sprycel (dasatinib) to Include Five-Year First-Line and Seven-Year Second-Line Efficacy and Safety Data in Chronic Myeloid Leukemia in Chronic Phase. 8/12/15 4:15 pm EDT. US Food and Drug Administration Extends Action Date for Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Untreated Advanced Melanoma. 8/4/15 8:00 am EDT. 8/3/15 9:00 am EDT. 7/29/15 7:00 pm EDT. 7/27/15 7:00 am EDT. 7/24/15 2:06 pm EDT.

INTERNAL PAGES

news.bms.com

1

Second-Generation Investigational HIV-1 Maturation Inhibitor Demonstrates Positive New Phase IIa Results, Supporting Continued Development | BMS Newsroom

http://news.bms.com/press-release/second-generation-investigational-hiv-1-maturation-inhibitor-demonstrates-positive-new

Second-Generation Investigational HIV-1 Maturation Inhibitor Demonstrates Positive New Phase IIa Results, Supporting Continued Development. Investigational agent BMS-955176 represents a novel approach since it is designed to inhibit HIV-1 replication as compared to currently available treatments. Tuesday, July 21, 2015 2:00 pm EDT. PRINCETON, N.J. PRINCETON, N.J.- ( BUSINESS WIRE. C/mL from baseline through study discharge (Day 42). The standard of care (SOC) control of atazanavir 300 mg and ritonavi...

2

European Medicines Agency Validates Two Parallel Type II Variation Applications to Extend the Opdivo (nivolumab) Indication in Europe | BMS Newsroom

http://news.bms.com/press-release/european-medicines-agency-validates-two-parallel-type-ii-variation-applications-extend

European Medicines Agency Validates Two Parallel Type II Variation Applications to Extend the Opdivo (nivolumab) Indication in Europe. Opdivo in previously treated non-squamous, non-small cell lung cancer (NSCLC) and. Opdivo in combination with. Yervoy (ipilimumab) in advanced melanoma. Thursday, July 23, 2015 6:30 am EDT. PRINCETON, N.J. PRINCETON, N.J.- ( BUSINESS WIRE. Validation of the applications confirms that the submissions are complete and starts the EMA's centralized review process. The type II...

3

Bristol-Myers Squibb and The Leukemia & Lymphoma Society Announce Charitable Donation to Support Critical Routine Testing and Awareness for Chronic Myeloid Leukemia Patients | BMS Newsroom

http://news.bms.com/press-release/bristol-myers-squibb-and-leukemia-lymphoma-society-announce-charitable-donation-suppor

Bristol-Myers Squibb and The Leukemia and Lymphoma Society Announce Charitable Donation to Support Critical Routine Testing and Awareness for Chronic Myeloid Leukemia Patients. Tuesday, August 4, 2015 8:00 am EDT. PRINCETON, N.J. and WHITE PLAINS, N.Y. PRINCETON, N.J. and WHITE PLAINS, N.Y.- ( BUSINESS WIRE. With the life expectancy of more CML patients increasing, the need for routine PCR testing is very important to ensure optimal treatment results, said Laura Bessen, MD, vice president, head of U....

4

AstraZeneca and Bristol-Myers Squibb Announce Top Line Results for SAVOR-TIMI-53 Cardiovascular Outcomes Trial of Onglyza® (saxagliptin) | BMS Newsroom

http://news.bms.com/press-release/astrazeneca-and-bristol-myers-squibb-announce-top-line-results-savor-timi-53-cardiovas&t=635072299828038806

AstraZeneca and Bristol-Myers Squibb Announce Top Line Results for SAVOR-TIMI-53 Cardiovascular Outcomes Trial of Onglyza (saxagliptin). Wednesday, June 19, 2013 2:02 am EDT. PRINCETON, N.J. and WILMINGTON, Del. PRINCETON, N.J. and WILMINGTON, Del.- ( BUSINESS WIRE. NYSE: BMY) and AstraZeneca. NYSE: AZN) today announced top line results of the Phase 4 SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) clinical trial of Onglyza. Is indicated as an adjun...

5

Investigational PD-1 Immune Checkpoint Inhibitor Nivolumab Receives U.S. FDA Breakthrough Therapy Designation for Hodgkin Lymphoma | BMS Newsroom

http://news.bms.com/press-release/rd-news/investigational-pd-1-immune-checkpoint-inhibitor-nivolumab-receives-us-fda-bre

Investigational PD-1 Immune Checkpoint Inhibitor Nivolumab Receives U.S. FDA Breakthrough Therapy Designation for Hodgkin Lymphoma. Designation granted for nivolumab for the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant followed by brentuximab. Wednesday, May 14, 2014 5:00 pm EDT. PRINCETON, N.J. PRINCETON, N.J.- ( BUSINESS WIRE. The Breakthrough Therapy Designation granted by the FDA for nivolumab continues to support the development of innovative approache...

UPGRADE TO PREMIUM TO VIEW 4 MORE

TOTAL PAGES IN THIS WEBSITE

9

OTHER SITES

news.bmamkt.com

BMA Marketing - Newsletters

BMA Marketing - Newsletters. Http:/ news.bmamkt.com/.

news.bme.com

ModBlog | BME: Tattoo, Piercing and Body Modification News

Skip to primary content. Skip to secondary content. Wedding ring microdermals, the new trend? March 14, 2018. There’s been a bit of buzz lately from some less than reputable news sites. I was approached by Refinery29. In order to comment on the subject, and after seeing the final article printed to seem almost positive towards the idea, I feel like the whole story should be told. (And, you know, I already wrote the whole thing). Here is the original interview in its entirety:. Recovery time with most pie...

news.bmicc.cn

国家人口与健康科学数据共享平台

Cell Research 细胞中心粒或为另一生物. Cell Research 细胞中心粒或为另一生物信使携带生物信息的可能不仅只有基因，一种被称为中心粒的细胞结构，或许也可充当信息在细胞代际间传递的. Cell Research 细胞中心粒或为另一生物信使. Cell Research 细胞中心粒或为另一生物信使携带生物信息的可能不仅只有基因，一种被称为中心粒的细胞结构，或许也可充当信息在细胞代际间传递的载体。 Journal of Immunology 上海巴斯德所发现调控I型干扰素表达和抗病毒反应的新机制. Journal of Immunology 上海巴斯德所发现调控I型干扰素表达和抗病毒反应的新机制病毒是严重危害人类健康的杀手之一，I型干扰素是调节抗病毒免疫的关键因子。 Journal of Cell Science 硫酸酶1能通过配位体影响规范和非规范Wnt信号. Journal of Cell Science 硫酸酶1能通过配位体影响规范和非规范Wnt信号 Wnt信号在胚胎发育和扮演着重要的角色，同时在人类疾病过程中产生时候表现为失去调控。

news.bmn.ir

بنیاد ملی نخبگان

همايش ملي نخبگان جوان. اولين همايش ملي نخبگان جوان. دومين همايش ملي نخبگان جوان. سومين همايش ملي نخبگان جوان. چهارمين همايش ملي نخبگان جوان. پنجمين همايش ملي نخبگان جوان. ششمين همايش ملي نخبگان جوان. جشنواره و نمايشگاه ملي نوآوري و شكوفايي. اولين جشنواره و نمايشگاه ملي نوآوري و شكوفايي. دومين جشنواره و نمايشگاه ملي نوآوري و شكوفايي. سومين جشنواره و نمايشگاه ملي نوآوري و شكوفايي. چهارمين جشنواره و نمايشگاه ملي نوآوري و شكوفايي. جشنواره هاي منطقه اي اختراعات. جشنواره هاي منطقه اي اختراعات كوهساران. دكتر ست...

news.bmotorsports.com

Ballenger Motorsports | High Performance Electronics

Skip to primary content. Skip to secondary content. Metric Fast Response Intake Air Temperature Sensor. July 24, 2015. The Ballenger Motorsports Fast-Response GM Delphi / Packard Intake Air Temperature Sensor ( SNSR-02057. Is a popular item. It combines high quality, rapid response, and reliability all at an excellent price point. It shares the same excellent features of our standard version, except with a metric M14 x 1.5 thread. Both the metric and standard sensors are genuine Delphi. July 23, 2015.

news.bms.com

BMS Newsroom |

8/13/15 8:00 am EDT. FDA Approves U.S. Product Labeling Update for Sprycel (dasatinib) to Include Five-Year First-Line and Seven-Year Second-Line Efficacy and Safety Data in Chronic Myeloid Leukemia in Chronic Phase. 8/12/15 4:15 pm EDT. US Food and Drug Administration Extends Action Date for Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Untreated Advanced Melanoma. 8/4/15 8:00 am EDT. 8/3/15 9:00 am EDT. 7/29/15 7:00 pm EDT. 7/27/15 7:00 am EDT. 7/24/15 2:06 pm EDT.

news.bmsaudio.com

BMS Audio News

Neues rund um die Beschallungstechnik. Besucherführungssystem TOM-Audio TG-100 etour jetzt kostenlos testen. Tour Guide System TOM-Audio TG-100. Der kostenlose Test ist eine wesentliche Station bei der Beschaffung einer Führungsanlage. Schließlich muss sichergestellt sein, dass die Anlage, in der vorgesehenen Umgebung, zuverlässig funktioniert. Außerdem gilt es abzuprüfen ob das Handling den persönlichen Vorstellungen entspricht und ausreichend Zubehör zur Verfügung steht. Sie sparen hier zwischen 20.

news.bmw.co.jp

BMW JAPAN : 最新情報

BMW "MISSION TO DRIVE" フェア. トムクルーズ主演の大人気シリーズ最新作ミッションインポッシブル/ローグネイションがいよいよ8月7日金から日本で公開。地図データアップデートプログラムに、このたび2年間更新料が無料になる 2年間アップデートプログラムが新登場。電気自動車の常識を覆す、革新のBMW i3に特別なファイナンスプランが登場しました。 2015年7月より、ニュー 1シリーズ、3シリーズ、X1も、 BMW 4 YOU. *1の対象に。今、BMW 6シリーズ従来モデルをご成約いただいた方に、特別なプレゼント。 BMW 4シリーズ Style Edge xDrive デビューフェア. 美しさと機能性を併せ持つ4ドアクーペを、スポーティなスタイリングで演出した BMW 4シリーズグランクーペ M Sport。 BMW 5シリーズのクリーンディーゼルモデルを魅力的な価格で。 BMW 5シリーズのクリーンディーゼルモデルが新しい価格で登場しました。ニュー BMW アクティブツアラークリーンディーゼルモデルが登場. 豊かなオー...

news.bmw.co.uk

BMW News

Cookies on the BMW UK website. We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on the BMW UK website. However, if you would like to, you can change your cookie settings at any time. You can find detailed information about how cookies are used on this website by reading our Privacy Policy. BMW 5 SERIES SALOON WINS. CAR OF THE YEAR 2017 AWARD. BMW 5 SERIES SALOON WINS. BMW i3...

news.bmw.it

BMW News

BMW Group al NAIAS 2017 di Detroit con Nuova BMW Serie 5 Berlina e BMW Concept X2. 04 January, 2017. Appuntamento da non perdere al NAIAS 2017 di Detroit con le novità targate BMW, per iniziare l’anno nuovo con…. Oltre gli auguri, vi facciamo una promessa. Anche tra 100 anni in ogni BMW ritroverete le stesse emozioni. 21 December, 2016. Il futuro è appena iniziato. Il futuro è una vittoria emozionante. È una canzone, un testo, un video,…. XDriveAlps2Alps. Uscite a divertirvi sulla neve, con BMW xDrive.

news.bmwoffreehold.com

BMW of Freehold: August Newsletter

888-829-8850 4225 US Highway 9, Freehold, NJ 07728. BMW of Freehold: August Newsletter. BMW of Freehold: August Newsletter. BMW of Freehold: July Newsletter. BMW of Freehold: June Newsletter. BMW of Freehold: May Newsletter. BMW of Freehold: April Newsletter. Help BMW of Freehold Support the BMW ‘Drive for Team USA’ Event. The 2016 BMW X3 continues BMW’s sports activity vehicle philosophy by applying the style, luxury, and driving dynamics of the carmaker’s sedans and coupes to a high-riding crossover.